Acromegaly Caused by a Growth Hormone-releasing Hormone-secreting Carcinoid Tumor: Case Report

Neurosurgery ◽  
2002 ◽  
Vol 50 (6) ◽  
pp. 1356-1360 ◽  
Author(s):  
Thomas J. Altstadt ◽  
Biagio Azzarelli ◽  
Carl Bevering ◽  
James Edmondson ◽  
Paul B. Nelson

Abstract OBJECTIVE AND IMPORTANCE We describe a patient with acromegaly and pituitary hyperplasia secondary to a growth hormone-releasing hormone-secreting gastrointestinal carcinoid tumor. This case report illustrates the importance of including this rare clinical syndrome in the differential diagnosis of acromegaly for patients with suspected or known neuroendocrine tumors. CLINICAL PRESENTATION A 19-year-old, Asian-American, male patient with a 2-year history of a nonresectable, metastatic, intestinal carcinoid tumor presented with complaints of headaches, arthralgias, sweats, and changing features. The examination revealed a young subject with acromegalic features, without visual field deficits. Magnetic resonance imaging revealed a diffuse sellar mass that extended suprasellarly to compress the optic chiasm. Endocrinological studies demonstrated a growth hormone level of more than 100 ng/ml and an inappropriately elevated growth hormone-releasing hormone level. INTERVENTION The patient underwent transsphenoidal resection of the pituitary mass for diagnostic and decompressive purposes. The pathological examination revealed pituitary hyperplasia, without evidence of an adenoma. Therapy with long-acting repeatable octreotide (Sandostatin LAR; Novartis AG, Basel, Switzerland) was initiated postoperatively, to further control the acromegaly and carcinoid tumor. The soft-tissue swelling resolved, and the patient remained free of headaches, arthralgias, and sweats at the 6-month follow-up examination. CONCLUSION Ectopic acromegaly is a rare syndrome that must be recognized by neurosurgeons because its treatment differs from that of classic pituitary acromegaly. We describe a patient for whom this syndrome was documented with magnetic resonance imaging, endocrinological testing, and pathological examinations.

Neurosurgery ◽  
2002 ◽  
Vol 50 (6) ◽  
pp. 1356-1360
Author(s):  
Thomas J. Altstadt ◽  
Biagio Azzarelli ◽  
Carl Bevering ◽  
James Edmondson ◽  
Paul B. Nelson

2021 ◽  
Vol 10 (1) ◽  
pp. 52-54
Author(s):  
Shankar Poudel ◽  
Upama Sangroula ◽  
Ashik Rajak

Kallmann syndrome is a rare genetically inherited condition characterized by hypogonadotrophic hypogonadism and anosmia or hyposmia. It is due to failure of migration of gonadotrophic releasing hormone neuron and olfactory neuron to hypothalamus. This case reports a 39-year-old Maldivian adult with clinical features of Kallmann syndrome and magnetic resonance imaging brain showing absence of olfactory sulcus and bulb.


2002 ◽  
Vol 10 (3) ◽  
pp. 273-276 ◽  
Author(s):  
Anil Bhansali ◽  
S Singh Rana ◽  
Sujit Bhattacharya ◽  
Rajgopal Muralidharan ◽  
Radharaman J Dash ◽  
...  

Bronchial carcinoids usually present with pulmonary symptoms. Neurohumoral manifestations in the form of acromegaly and Cushing's syndrome are rarely encountered. We report a case of bronchial carcinoid with features of acromegaly due to ectopic production of growth hormone-releasing hormone. Surgical resection of the lung lesion resulted in regression of acromegalic features, normalization of growth hormone secretory dynamics, and remarkable diminution of pituitary size seen on magnetic resonance imaging.


2014 ◽  
Vol 38 (2) ◽  
pp. 212-214 ◽  
Author(s):  
Mehmet Beyazal ◽  
Necip Pirinççi ◽  
Alpaslan Yavuz ◽  
Sercan Özkaçmaz ◽  
Gülay Bulut

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Tomoyuki Ishida ◽  
Jun Kanamori ◽  
Hiroyuki Daiko

Abstract Background Management of postoperative chylothorax usually consists of nutritional regimens, pharmacological therapies such as octreotide, and surgical therapies such as ligation of thoracic duct, but a clear consensus is yet to be reached. Further, the variation of the thoracic duct makes chylothorax difficult to treat. This report describes a rare case of chylothorax with an aberrant thoracic duct that was successfully treated using focal pleurodesis through interventional radiology (IVR). Case presentation The patient was a 52-year-old man with chylothorax after a thoracoscopic oesophagectomy for oesophageal cancer. With conventional therapy, such as thoracostomy tube, octreotide or fibrogammin, a decrease in the amount of chyle was not achieved. Therefore, we performed lymphangiography and pleurodesis through IVR. The patient appeared to have an aberrant thoracic duct, as revealed by magnetic resonance imaging (MRI); however, after focal pleurodesis, the leak of chyle was diminished, and the patient was discharged 66 days after admission. Conclusions Chylothorax remains a difficult complication. Focal pleurodesis through IVR can be one of the options to treat chylothorax.


Sign in / Sign up

Export Citation Format

Share Document